Sarepta Therapeutics
Market Cap
US$7.7b
Last Updated
2020/03/31 00:30 UTC
Data Sources
Company Financials +
Executive Summary
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Sarepta Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRPT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.3%
SRPT
4.7%
US Biotechs
7.2%
US Market
1 Year Return
-19.7%
SRPT
1.8%
US Biotechs
-10.4%
US Market
Return vs Industry: SRPT underperformed the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: SRPT underperformed the US Market which returned -10.4% over the past year.
Shareholder returns
| SRPT | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.3% | 4.7% | 7.2% |
| 30 Day | -13.9% | -3.5% | -12.6% |
| 90 Day | -23.7% | -5.4% | -19.4% |
| 1 Year | -19.7%-19.7% | 2.6%1.8% | -8.5%-10.4% |
| 3 Year | 242.2%242.2% | 14.0%11.1% | 15.8%8.3% |
| 5 Year | 580.9%580.9% | -3.6%-7.9% | 35.8%21.0% |
Price Volatility Vs. Market
How volatile is Sarepta Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Have Insiders Been Buying Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares?1 month ago | Simply Wall St
Imagine Holding Sarepta Therapeutics (NASDAQ:SRPT) Shares While The Price Zoomed 690% Higher1 month ago | Simply Wall St
Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?Valuation
Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SRPT ($98.52) is trading below our estimate of fair value ($315.9)
Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRPT is overvalued based on its PB Ratio (9.1x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
59.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: SRPT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SRPT's is expected to become profitable in the next 3 years.
Revenue vs Market: SRPT's revenue (37.2% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: SRPT's revenue (37.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRPT's Return on Equity is forecast to be very high in 3 years time (46.2%).
Next Steps
Past Performance
How has Sarepta Therapeutics performed over the past 5 years?
-28.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRPT is currently unprofitable.
Growing Profit Margin: SRPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of -28.6% per year.
Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: SRPT has a negative Return on Equity (-87.4%), as it is currently unprofitable.
Next Steps
Financial Health
How is Sarepta Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($1.5B) exceed its short term liabilities ($264.8M).
Long Term Liabilities: SRPT's short term assets ($1.5B) exceed its long term liabilities ($739.9M).
Debt to Equity History and Analysis
Debt Level: SRPT's debt to equity ratio (83.3%) is considered high.
Reducing Debt: SRPT's debt to equity ratio has increased from 2.6% to 83.3% over the past 5 years.
Balance Sheet
Inventory Level: SRPT has a low level of unsold assets or inventory.
Debt Coverage by Assets: SRPT's debt is covered by short term assets (assets are 2.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SRPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Doug Ingram (56yo)
2.67s
Tenure
US$1,433,872
Compensation
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 28, 2017. Mr. Ingram serves as Director of Relay Therapeutics, ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD1.43M) is below average for companies of similar size in the US market ($USD7.28M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.67yrs | US$1.43m | 0.51% $38.9m | |
| Executive VP | 7.25yrs | US$4.22m | 0.054% $4.2m | |
| Executive VP | 7.25yrs | US$3.13m | 0.032% $2.5m | |
| Executive VP & Chief Commercial Officer | 3.42yrs | US$3.12m | 0.0068% $522.6k | |
| Executive VP of R&D and Chief Medical Officer | 1.67yrs | US$6.67m | 0.0095% $726.4k | |
| Executive Vice President of Technical Operations | 0.25yr | no data | no data | |
| Senior VP of Corporate Affairs & Chief of Staff | 2.17yrs | no data | no data | |
| Senior Vice President of Global Health Policy and Government & Patient Affairs | 0.42yr | no data | no data | |
| Senior Vice President of Human Resources | 0.42yr | no data | no data | |
| Senior Vice President of Gene Therapy | 1yr | no data | no data |
1.9yrs
Average Tenure
54yo
Average Age
Experienced Management: SRPT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.67yrs | US$1.43m | 0.51% $38.9m | |
| Director | 0.17yr | no data | no data | |
| Chairwoman | 4.83yrs | US$502.15k | 0.17% $13.2m | |
| Chairman of Corporate Strategy Board & Non-Employee Director | no data | US$467.02k | 0.013% $993.8k | |
| Member of Strategic & Scientific Advisory Board | 4.58yrs | no data | no data | |
| Independent Director | 1.25yrs | US$731.38k | 0.0013% $101.9k | |
| Member of Strategic & Scientific Advisory Board | 4.58yrs | no data | no data | |
| Non-Employee Director | 4.67yrs | US$464.51k | 0.0070% $534.1k | |
| Member of Strategic & Scientific Advisory Board | 3yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 3yrs | no data | no data |
3.0yrs
Average Tenure
66.5yo
Average Age
Experienced Board: SRPT's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.1%.
Top Shareholders
Company Information
Sarepta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sarepta Therapeutics, Inc.
- Ticker: SRPT
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.663b
- Shares outstanding: 77.78m
- Website: https://www.sarepta.com
Number of Employees
Location
- Sarepta Therapeutics, Inc.
- 215 First Street
- Suite 415
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRPT | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 1997 |
| AB3A | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1997 |
| 0L35 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 1997 |
| AB3A | BRSE (Berne Stock Exchange) | Yes | Common Stock | CH | CHF | Jun 1997 |
Biography
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51, for the treatment of duchenne muscular dystrophy (DMD); and VYONDYS 53 for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Its products pipeline include Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD, micro-dystrophin gene therapy to treat peripheral neuromuscular diseases; SRP-9003, a gene therapy program for various types of limb-girdle muscular dystrophies; and LYS-SAF 302, a gene therapy program, which is in Phase 2/3 clinical trial to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with Nationwide Children’s Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; and GALGT2, a gene therapy program for the treatment of neuromuscular related disorders. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a license and collaboration agreement with Lysogene S.A., a gene therapy company for the treatment of orphan diseases of the central nervous system; license and collaboration agreement with Genethon to develop micro-dystrophin gene therapy products for the treatment of DMD; and a collaboration and license agreement with StrideBio, Inc. to develop in vivo adeno-associated virus based therapies. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/31 00:30 |
| End of Day Share Price | 2020/03/30 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.